Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to AlbuterolNot Yet Recruiting
NCT07787117N/AUpdated Aug 26, 2026
Sponsor: AstraZeneca
Asthma
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerRecruiting
NCT06350097Phase 3Updated Aug 26, 2026
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
United States, Australia, Brazil, Canada, China +14 more
National Acalabrutinib Observational StudyActive Not Recruiting
NCT05437250N/AUpdated Aug 26, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia
France
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine CarcinosarcomaActive Not Recruiting
NCT03668340Phase 2Updated Aug 25, 2026
Sponsor: Dana-Farber Cancer Institute
Uterine Cancer
United States
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightNot Yet Recruiting
NCT07784270Phase 3Updated Aug 25, 2026
Sponsor: AstraZeneca
Obesity or Overweight · Diabetes Mellitus, Type 2
United States, Argentina, Australia, Canada, Chile +11 more
Real-World Treatment Study of Koselugo (Selumetinib)Recruiting
NCT06360406N/AUpdated Aug 25, 2026
Sponsor: AstraZeneca
Neurofibromatosis 1 · Neurofibroma, Plexiform
South Korea
Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaRecruiting
NCT07088991N/AUpdated Aug 25, 2026
Sponsor: AstraZeneca
Neurofibromatosis
Russia
Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)Recruiting
NCT07633158N/AUpdated Aug 25, 2026
Sponsor: AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Germany
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON DatabaseRecruiting
NCT06548152N/AUpdated Aug 25, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia
France
DESTINY-PANTUMOUR04Recruiting
NCT07124000N/AUpdated Aug 25, 2026
Sponsor: AstraZeneca
Adenocarcinoma (NOS) · Anal Cancer · Bladder Cancer · Cervical Cancer
United States
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)Recruiting
NCT06079671Phase 3Updated Aug 25, 2026
Sponsor: AstraZeneca
Locally Advanced Cervical Cancer
United States, Brazil, Canada, China, Denmark +14 more
Benralizumab Airway Remodeling Study in Severe Eosinophilic AsthmaticsActive Not Recruiting
NCT03953300Phase 4Updated Aug 25, 2026
Sponsor: AstraZeneca
Asthma
United States, Canada, Denmark, Sweden, United Kingdom
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusRecruiting
NCT07784725Phase 3Updated Aug 25, 2026
Sponsor: AstraZeneca
Obesity or Overweight
United States, Argentina, Australia, Brazil, Bulgaria +11 more
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabRecruiting
NCT07391670Phase 1Updated Aug 25, 2026
Sponsor: AstraZeneca
Solid Tumours
Australia, Georgia, Poland, South Korea, Taiwan
Cardiovascular Assessment and Treatment During COPD Exacerbation to Improve Diagnosis and OutcomesActive Not Recruiting
NCT06723795NAUpdated Aug 25, 2026
Sponsor: Tel-Aviv Sourasky Medical Center
COPD (Chronic Obstructive Pulmonary Disease) · Cardiovascular Diseases
Israel
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical StudiesRecruiting
NCT07606066N/AUpdated Aug 25, 2026
Sponsor: AstraZeneca
Type 2 Diabetes
United States, Brazil, Hungary, India, Malaysia +2 more
REBECCA Real-world Early BrEast CanCer mAnagementRecruiting
NCT06856343N/AUpdated Aug 25, 2026
Sponsor: AstraZeneca
Breast Cancer
France
China Glomerulonephritis Kidney Transplant Recipient Cohort: A Prospective Multicenter Observational StudyNot Yet Recruiting
NCT07783737N/AUpdated Aug 25, 2026
Sponsor: AstraZeneca
Glomerulonephritis Kidney Transplant
An Open-label Study of AZD0120 in Adults With Multiple SclerosisRecruiting
NCT07224373Phase 1Updated Aug 25, 2026
Sponsor: AstraZeneca
Multiple Sclerosis
United States, Australia, Canada, Germany, United Kingdom
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and HyperinflationRecruiting
NCT07073950Phase 4Updated Aug 24, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease · Hyperinflation
Germany, United Kingdom
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)Active Not Recruiting
NCT05104866Phase 3Updated Aug 24, 2026
Sponsor: AstraZeneca
Breast Cancer
United States, Argentina, Belgium, Brazil, Canada +15 more
A Trial to Investigate Benralizumab in Children With Eosinophilic DiseasesRecruiting
NCT06512883Phase 3Updated Aug 24, 2026
Sponsor: AstraZeneca
Eosinophilic Granulomatosis With Polyangiitis (EGPA) · Hypereosinophilia Syndrome (HES)
United States, Brazil, Canada, France, India +5 more
PASS of Paediatric Patients Initiating SelumetinibActive Not Recruiting
NCT05388370N/AUpdated Aug 24, 2026
Sponsor: AstraZeneca
Neurofibromatosis Type 1
Austria, France, Germany, Israel, Italy +5 more
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First EventRecruiting
NCT07000357Phase 3Updated Aug 24, 2026
Sponsor: AstraZeneca
Cardiovascular Disease
United States, Argentina, Brazil, Bulgaria, Canada +31 more
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid MalignanciesActive Not Recruiting
NCT00463814Phase 1Updated Aug 24, 2026
Sponsor: AstraZeneca
Tumor · Cancer
United States, Netherlands, United Kingdom

Previous page Next page